|
|
Article: 3M Submits Supplemental New Drug Application to FDA for Aldara Cream for the Treatment of Actinic Keratosis.
- Article from:
- Business Wire
- Article date:
- May 5, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
ST. PAUL, Minn.--(BUSINESS WIRE)--May 5, 2003
- First Immune Response Modifier to Seek Indication to Treat
Common Precursor to Skin Cancer -
3M announced today that the company has submitted a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) to market Aldara cream, an immune response modifier (IRM), for the treatment of actinic keratosis (AK). AK is a common, potentially serious skin condition affecting as many as 10 million Americans each year. Aldara, currently the leading prescription treatment for external genital and perianal warts, is the first IRM ...